STRATEGIC NEWS WATCH — July 23, 2026
|
Eli Lilly’s retatrutide posted up to 22.6% weight loss across two Phase 3 trials, while J&J’s bispecific combo cut myeloma progression risk 89%, GSK landed its first lung cancer approval, and Roche declared its pipeline too full to chase big M&A. Today’s top developments:
|
What to Watch
- Retatrutide FDA filing (Q1 2027) — Lilly plans a broad application spanning obesity, knee osteoarthritis pain, and obstructive sleep apnea; the key question is whether it strengthens the package with cardiovascular outcomes data, and how discontinuation rates near 12–13.5% shape the label.
- J&J bispecific combo regulatory path — With an 89% reduction in progression-or-death risk in hand, the timing of J&J’s submission for earlier-line myeloma — and how payers respond to combination pricing against established CAR-T platforms — bears close monitoring.
- GSK oncology momentum — The Jideytro approval validates the Nuvalent thesis; expect GSK to advance other Nuvalent-derived assets and pit zidesamtinib against incumbents like entrectinib and crizotinib in ROS1 NSCLC.
- FDA peptide advisory committee (week of July 23) — The panel weighing compounding restrictions on seven peptides could unlock a large telehealth market; its recommendation and the read-through for Hims & Hers and its peers merit attention.
- Oral PCSK9 race — The Evogene–ELEO collaboration on oral small-molecule PCSK9 inhibitors signals intensifying competition to displace injectable antibodies; the open question is whether AI-assisted design can crack a target long considered hard to drug orally.
This brief highlights the edition’s top stories. Read the full July 23, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.